Gangagen Biotechnologies Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 08-07-2024
- Paid Up Capital ₹ 4.40 Cr
as on 08-07-2024
- Company Age 24 Year, 17 Days
- Last Filing with ROC 31 Dec 2022
- Revenue 3.74%
(FY 2019)
- Profit -36.88%
(FY 2019)
- Ebitda 44.24%
(FY 2019)
- Net Worth 5.56%
(FY 2019)
- Total Assets 7.14%
(FY 2019)
About Gangagen Biotechnologies
The Company is engaged in the Life Science Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2022. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 4.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Tanjore Soundararajan, Jayasheela Manur, Kumud Sampath, and Two other members serve as directors at the Company.
- CIN/LLPIN
U72100KA2000PTC027824
- Company No.
027824
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Sep 2000
- Date of AGM
26 Jun 2023
- Date of Balance Sheet
31 Dec 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Gangagen Biotechnologies?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tanjore Soundararajan  | Director | 23-Apr-2015 | Current |
| Jayasheela Manur | Director | 27-Mar-2007 | Current |
| Kumud Sampath | Director | 15-Dec-2020 | Current |
Leow Jeffrey  | Director | 15-Dec-2020 | Current |
| Suchad Chiaranussati | Director | 15-Dec-2020 | Current |
Financial Performance and Corporate Structure Insights of Gangagen Biotechnologies.
Gangagen Biotechnologies Private Limited, for the financial year ended 2019, experienced modest growth in revenue, with a 3.74% increase. The company also saw a substantial fall in profitability, with a 36.88% decrease in profit. The company's net worth moved up by a moderate rise of 5.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gangagen Biotechnologies?
In 2019, Gangagen Biotechnologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ahammune Biosciences Private Limited
Active
8 years 5 months Tanjore Soundararajan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gangagen Biotechnologies?
Gangagen Biotechnologies has a workforce of 38 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Oct 08, 2009, Gangagen Biotechnologies has raised a total of ₹ 6.8 Cr, with the most recent deal valued at ₹ 3.4 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
